Biologics, an alternative therapeutic approach for oral lichen planus

J Oral Pathol Med (2011) 40: 521–524 Oral lichen planus (OLP) is generally accepted as a chronic and T‐cell‐mediated autoimmune disease, whose immunopathogenesis may involve antigen presentation, T‐cell activation and migration as well as, possibly, tumor necrosis factor‐alpha (TNF‐α)‐induced kerati...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oral pathology & medicine 2011-08, Vol.40 (7), p.521-524
Main Authors: Zhang, Jing, Zhou, Gang, Du, Ge-Fei, Xu, Xue-Yi, Zhou, Hong-Mei
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antigen presentation
Apoptosis
Autoimmune diseases
Autoimmune Diseases - drug therapy
Biological and medical sciences
Biological Products - therapeutic use
biologics
Dentistry
Dermatology
Humans
Immunologic Factors - therapeutic use
Immunopathogenesis
Keratinocytes
Leukocyte migration
Lichen planus
Lichen Planus, Oral - drug therapy
Lichen Planus, Oral - immunology
Lymphocytes T
Medical sciences
Migration
oral lichen planus
Otorhinolaryngology. Stomatology
pathogenesis
Psoriasis. Parapsoriasis. Lichen
Recombinant Fusion Proteins - therapeutic use
T cells
T-Lymphocytes - immunology
treatment
Tumor necrosis factor- alpha
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:J Oral Pathol Med (2011) 40: 521–524 Oral lichen planus (OLP) is generally accepted as a chronic and T‐cell‐mediated autoimmune disease, whose immunopathogenesis may involve antigen presentation, T‐cell activation and migration as well as, possibly, tumor necrosis factor‐alpha (TNF‐α)‐induced keratinocytes apoptosis. However, present treatment options for OLP are far from being satisfactory. Recent advances in understanding the pathogenesis of OLP, progress in biologics, and the success of biologic therapies in OLP indicate that biologic agents are facing expanding indications in OLP. In this review, we mainly discuss the role of T cells in the pathogenesis of OLP and several biologic therapies that directly and/or indirectly target T cells to treat OLP.
ISSN:0904-2512
1600-0714
DOI:10.1111/j.1600-0714.2011.01029.x